Advantages of low-cost generic tenofovir instead of D4T for first-line antiretroviral therapy in Burma: a 2-year experience.
Stephen
S
Moore
Myo M
MM
Myint
Naw H
NH
Galau
D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000191:economics; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000191:economics*; D023241:Antiretroviral Therapy, Highly Active / Q000191:economics; D003362:Cost-Benefit Analysis; D015658:HIV Infections / Q000188:drug therapy / Q000191:economics*; D006801:Humans; D002052:Myanmar; D063065:Organophosphonates / Q000008:administration & dosage / Q000191:economics*; D000068698:Tenofovir
D019380:Anti-HIV Agents; D063065:Organophosphonates; D000068698:Tenofovir; D000225:Adenine